Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Four hundred ninety eight children of 15 months to 5 years of age were immunized with 0.5 ml of b-CAPSATM I Haemophilus influenzae type b polysaccharide vaccine (Hib). Every other child received the vaccine subcutaneously (S.C.) and the alternates received the vaccine intramuscularly (I.M.). Two hundred and two (81.1%) children in the S.C. group and 198 (79.5%) children in the I.M. group returned for follow-up visits 48-72 hours after the immunization and had the adverse reactions documented. The rest were contacted by telephone. After matching for sex and age, we had 194 pairs (103 males and 91 females) in each group with a mean age difference between the pairs of 0.4 month. Based on paired comparisons, pain, manifested as crying, at the time of inoculation was more frequent with intramuscular administration (p less than 0.01). Tenderness at the injection site occurred in 4 children in the I.M. group but none in the S.C. group and was of borderline statistical significance (p = 0.06). The occurrence of other adverse reactions was not significantly different between the two groups. The findings of this study suggest that subcutaneous injection is the method of choice for Hib vaccine administration.
 ...
PMID:Subcutaneous versus intramuscular administration of Haemophilus influenzae type b vaccine. 250 May 25

To ensure compliance and to reduce costs it is important, especially in less developed countries, that programs of child immunization should require as few clinic attendances and as few injections as possible. Therefore we have investigated whether a Haemophilus influenzae type b conjugate vaccine could be given safely and effectively with diphtheria-tetanus-pertussis vaccine (DTP). One hundred twenty-six Gambian infants were given both polyribosylribitol phosphate (PRP)-outer membrane protein complex (PedvaxHIB) and DTP on the same day at 8, 12 and 16 weeks of age; 60 were given the vaccines mixed in the syringe and 66 were given the vaccines separately. To minimize the injection volume the dose of PRP-OMPC used in both groups was 7.5 micrograms, which is half the usual dose. There were no significant differences in anti-PRP antibody titers between the groups after 1, 2 or 3 doses. The geometric mean titers of antibody for the two groups combined were 0.29 micrograms/ml 1 month after the first dose, 1.03 micrograms/ml after the second dose and 1.11 micrograms/ml after the third dose. Concentrations of antibodies to diphtheria, tetanus and pertussis 1 month after the third dose were not significantly different between the two groups. Systemic side effects were reported with equal frequency in the two groups and were similar to those reported elsewhere for DTP. Tenderness at the injection site was more common where the combined injection (0.75 ml) had been given than where DTP alone (0.5 ml) had been given. The main drawback to the use of these 2 vaccines together is the complexity of the mixing procedure used in this clinical trial.
 ...
PMID:Safety and immunogenicity of Haemophilus influenzae type B-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. 841 74